The purpose of the current study is to evaluate the clinical benefit of percutaneous catheter-based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) and end-stage renal failure.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years
Ability to give informed consent
Documented NVAF (paroxysmal, persistent, or permanent)
CHA2DS2VASc risk score ≥2
Chronic kidney disease KDOQI stage 5 (eGFR \<15 ml/min/1.73m2) with or without hemodialysis
You may not be if
Absolute contraindication to aspirin and/or clopidogrel
Comorbidities other than AF requiring chronic (N)OAC therapy e.g. mechanical heart valve prosthesis
